Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

233 Clinical Updates found
OncoKB, a database developed and maintained by investigators at MSK, helps match patients with targeted therapies based on the mutations found in their tumors.
Doctor and patient at MSK’s Multidisciplinary Brain Metastasis Clinic
Local control rates and overall survival (OS) were significantly higher for patients with brain metastases treated with adjuvant stereotactic radiosurgery (SRS) within two months of resection, compared to longer time intervals, according to our new study published recently in Neuro-Oncology Practice.
Medical oncologist Alexander Drilon is Chief of MSK’s Early Drug Development Service. He specializes in lung cancer and early-phase clinical trials
MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials.
Lead study author Andrea Cercek, MD, is Section Head, Colorectal Cancer and Co-Director of the Center for Young Onset Colorectal and Gastrointestinal at MSK
Early-onset colorectal cancer (CRC) is likely clinically and genomically indistinguishable from average-onset cancer, according to a recent study published in the Journal of the National Cancer Institute by MSK investigators.
Neurologist Dr. Adrienne Boire in her lab
MSK research team identifies unique markers of inflammation and neurodegeneration found in cerebrospinal fluid of cancer patients with altered mental status after initial SARS-CoV-2 infection, as likely cause of neurologic dysfunction.
MSK HPB surgeons
Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons.
Dr. Mark Bilsky with a patient
Surgical resection of symptomatic, benign intradural extramedullary (IDEM) spine tumors provides rapid, significant, and durable improvements in patient-reported outcomes.
David Solit, MD
Clinical Update
At Memorial Sloan Kettering Cancer Center, we have now analyzed more than 50,000 samples in our prospective cohort with MSK-IMPACT™.